Assembly Biosciences, Inc. discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV)infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
